{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:42:02Z","timestamp":1792172522480,"version":"4.4.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The combination of immune checkpoint inhibitors with chemotherapy is a standard first-line treatment for advanced esophageal squamous cell carcinoma. However, robust data regarding the efficacy and safety of this approach specifically in patients aged 75 years and older are scarce, as this population is frequently underrepresented in pivotal clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the real-world treatment outcomes and safety profile of first-line immunotherapy in patients aged \u226575 years with advanced esophageal squamous cell carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, single-center cohort study. Sixty-one patients aged \u226575 years with histologically confirmed, advanced esophageal squamous cell carcinoma (stage III\/IV) who initiated first-line immune checkpoint inhibitors (as monotherapy or combined with chemotherapy\/antiangiogenic therapy) between February 2021 and May 2025 were included. Assessments included tumor response per RECIST 1.1, progression-free survival, overall survival, and adverse events graded per the National Cancer Institute Common Toxicity Criteria v5.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median age was 80 years. The objective response rate was 45.9% (28\/61), and the disease control rate was 85.2%. After a median follow-up of 16.7 months, the median progression-free survival was 12.7 months (95% CI: 6.9-17.1), and the median overall survival was 17.7 months (95% CI: 10.7-22.8). Both progression-free survival and overall survival significantly differed among response groups (log-rank\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.0001). Treatment was generally tolerable. Any-grade immune-related adverse events occurred in 39.1% of patients, with grade \u22653 events in 1.6%. Non-immune toxicities were common (any grade 93.1%; grade \u22653 in 14.7%), primarily hematologic.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world cohort, first-line immunotherapy demonstrated promising efficacy and a manageable safety profile in patients aged \u226575 years with advanced esophageal squamous cell carcinoma. These findings provide valuable preliminary evidence supporting the use of immune checkpoint inhibitors in this understudied population and highlight the need for prospective validation to optimize therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1753874","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:34:41Z","timestamp":1768372481000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["First-line immune checkpoint inhibitors in older adults (\u226575 years) with advanced esophageal squamous cell carcinoma: efficacy and safety"],"prefix":"10.3389","volume":"15","author":[{"given":"Lin-lin","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Putian University","place":["Putian, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-cai","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Affiliated Hospital of Putian University","place":["Putian, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-dan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Research, Affiliated Hospital of Putian University","place":["Putian, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"743","author":"Bray","year":"2024","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/s0140-6736(24)02226-8","article-title":"Oesophageal cancer","volume":"40410466","author":"Yang","year":"2024","journal-title":"Lancet (London England)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2019.03.040","article-title":"Pharmacokinetics of omega-3 fatty acids in patients with severe sepsis compared with healthy volunteers: A prospective cohort study","volume":"393","author":"Parikh","year":"2020","journal-title":"Clin Nutr (Edinburgh Scotland)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","article-title":"The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020","volume":"1633","author":"Morgan","year":"2022","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"39110125","author":"Allemani","year":"2018","journal-title":"Lancet (London England)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S214579","article-title":"Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities","volume":"12","author":"Jiao","year":"2019","journal-title":"OncoTargets Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12119","article-title":"Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma","volume":"4012","author":"Zhang","year":"2020","journal-title":"Cancer Commun (London England)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(21)00378-2","article-title":"Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial","volume":"73","author":"Meng","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"32610","author":"Luo","year":"2021","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"39810302","author":"Sun","year":"2021","journal-title":"Lancet (London England)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"3865","author":"Doki","year":"2022","journal-title":"New Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ (Clinical Res ed)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"245","author":"Xu","year":"2023","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2019.05.013","article-title":"Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: A meta-analysis","volume":"113","author":"Kasherman","year":"2020","journal-title":"J Geriatric Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-020-00794-x","article-title":"Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)","volume":"181","author":"Takahashi","year":"2021","journal-title":"Esophagus"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02797-y","article-title":"First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study","volume":"303","author":"Li","year":"2024","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"51","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s00262-025-03970-z","article-title":"Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies","volume":"744","author":"Lu","year":"2025","journal-title":"Cancer Immunology Immunother: CII"},{"key":"B19","unstructured":"Esophageal cancer diagnosis and treatment guidelines\n          \n          2024"},{"key":"B20","unstructured":"Guidelines for the management of toxicity associated with immune checkpoint inhibitors\n          \n          2023"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"3622","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.887525","article-title":"Efficacy and safety of radiotherapy\/chemoradiotherapy combined with immune checkpoint inhibitors for locally advanced stages of esophageal cancer: A systematic review and meta-analysis","volume":"12","author":"Wu","year":"2022","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1039020","article-title":"Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2023.111162","article-title":"Case report of radiotherapy combined with anlotinib and immunotherapy for a patient with esophageal cancer and esophageal fistula","volume":"205","author":"He","year":"2024","journal-title":"Appl Radiat Isotopes: Including Data Instrument Methods Use Agriculture Industry Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1753874\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:39:37Z","timestamp":1771911577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1753874\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":24,"alternative-id":["10.3389\/fonc.2025.1753874"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1753874","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"1753874"}}